Subscribe to our Email Alerts
Menu
Home
About Us
Company Overview
Company Values
Board of Directors
Executive Management
Corporate Directory
Products
DAYBUE® (trofinetide)
Pipeline
Pipeline
NNZ-2591
Phelan-McDermid Syndrome
Angelman Syndrome
Pitt Hopkins Syndrome
Hypoxic-ischemic encephalopathy
Prader-Willi Syndrome
Compassionate Use
Science
Science Behind Neuren's Products
Trofinetide Published Studies & Presentations
Rett Syndrome
NNZ-2591Published Studies & Presentations
Phelan-McDermid Syndrome
Pitt Hopkins Syndrome
Angelman Syndrome
Investors
Investor Dashboard
Share Price Information
ASX Announcements
Annual and Interim Reports
Investor Presentations
Corporate Governance
Analyst Coverage
Shareholder Services
News & Media
Media
Contact
Contact Us
Email Alerts
Investors
Home
>
Investors
>
ASX Announcements
Investor Dashboard
Share Price Information
ASX Announcements
Annual and Interim Reports
Investor Presentations
Corporate Governance
Analyst Coverage
Shareholder Services
ASX Announcements
Filter by Year:
2025
2024
2023
2022
2021
2020
2019
2018
Older
Feb 28, 2025
2024 Full Year Results webinar
Feb 28, 2025
Neuren receives DAYBUE sales milestone payment of US$50m
Feb 28, 2025
2024 results - A$166m comprehensive income for shareholders
Feb 28, 2025
Appendix 4E and 2024 full year accounts
Feb 27, 2025
Neuren 2024 results investor webinar on 28 February 2025
Feb 27, 2025
DAYBUE (trofinetide) 2024 net sales US$348 million
Feb 25, 2025
Becoming a substantial holder
Feb 24, 2025
Neuren receives Rare Pediatric Disease Designation from FDA
Feb 19, 2025
Fast Track granted by FDA for NNZ-2591 in Pitt Hopkins
Feb 07, 2025
Priority Review Voucher sale proceeds received
Previous
1
2
3
4
5
6
7
8
9
10
11
12
13
Next
